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Abstract 
Arsenic is a highly toxic and carcinogenic metalloid widely dispersed in the environment, conta-
minating water and soil and accumulating in crops. Paradoxically, arsenic is also part of modern 
therapy and employed in treating numerous ailments and diseases. Hence, inventing strategies to 
tune cellular arsenic uptake based on purpose is striking. Here, we describe an approach in which 
the arsenite uptake can be increased using a MAPK inhibitor. Employing microfluidic flow cham-
bers in combination with optical tweezers and fluorescent microscopy, we elevated the influx of 
arsenite into the yeast Saccharomyces cerevisiae cells following short-term treatment with a Hog1 
kinase inhibitor. The increase in arsenite uptake was followed on arsenite triggered redistribu-
tion of a reporter protein, Hsp104-GFP, which was imaged over time. The effect was even more 
pronounced when the yeast mother and daughter cells were analyzed disjointedly, an opportunity 
provided owing to single-cell analysis. Our data firstly provide a strategy to increase arsenite up-
take and secondly show that arsenite triggered aggregates, previously shown to be sites of dam-
aged proteins, are distributed asymmetrically and less accumulated in daughter cells. Inventing 
approaches to tune arsenite uptake has a great value for its use in environmental as well as medi-
cal applications. 
 
 
 
*Corresponding author. 
D. Ahmadpour et al. 
 
 60 
Keywords 
Mitogen Activated Protein Kinase (MAPK); Hog1; MAPK inhibitor; Arsenic; Microfluidics 
 
 
1. Introduction 
Arsenic is a toxic metalloid broadly spread in the environment [1] and its concentration is higher than the per-
missible levels in many regions of the world [2] [3]. Human is usually exposed to arsenic through industrial ac-
tivities, by drinking water that has percolated through arsenic-rich soil [4] [5] or by consuming arsenic accumu-
lating crops such as rice, wheat, fruits and vegetables [6]. Long-term exposure to arsenic causes a number of 
human diseases e.g. diabetes [7], kidney and cardiovascular diseases [8]. It is also associated with liver, lung, 
skin and bladder cancers [9]. Paradoxically, arsenic compounds have a history of over 2000 years of use as 
medicine [10]. In particular, it is used in the treatment of diseases caused by protozoan parasites [11]. The or-
ganic arsenical Melarsoprol is used as first line treatment against late stage human African trypanosomiasis [12] 
[13]. Arsenic trioxide is also the active ingredient in the chemotherapeutic drug Trisenox®, which is used for the 
treatment of acute promyelocytic leukaemia [14] [15]. Arsenic trioxide also shows high cytotoxic effect in small 
cell lung carcinoma, which otherwise responds very poorly to treatments [16]. Similarly, it has recently been 
shown that arsenic can be a choice of therapy for treating other forms of cancer [10] [17]. However, the effi-
ciency of response to arsenic-based drugs depends partly on the levels of cellular arsenic uptake [18]. Hence, in 
order to produce safe crops with low arsenic accumulation, to gain a more effective therapy when the cancer 
cells or parasites show resistance to arsenic-based drugs and to engineer arsenic accumulating plants for phyto-
remediation purposes, innovating approaches to tune the uptake of arsenic upon purpose is imperative. Here, we 
addressed this issue by inventing an approach with which the cellular uptake of arsenite is increased employing 
a Mitogen Activated Protein Kinase (MAPK) inhibitor. 
Arsenic as the trivalent form (arsenite As(III)) is the most prominent and toxic form [1]. In the eukaryotic 
model organism Saccharomyces cerevisiae (budding yeast), aquaglyceroporin Fps1 is the major entry route for 
arsenite (As(III)) in the presence of glucose [19]. Aquaglyceroporins have also been indicated as the entry route 
for As(III) in many other organisms e.g. plants [20], mammals [21], and humans [22]. Moreover, the activity of 
arsenite influx and detoxification systems is controlled by signaling proteins. In a previous study, we have 
shown that deleting the gene encoding for the MAPK Hog1 in S. cerevisiae results in arsenite sensitivity due to 
elevated intracellular arsenite levels and that the increased arsenite influx is dependent on the aquaglyceroporin 
Fps1 [23]. Further, we provided evidence that MAPK Hog1 is activated upon arsenite exposure. Hog1 phos-
phorylation then negatively regulates Fps1-mediated arsenite uptake and Hog1 phosphorylation as well as its 
kinase activity are critical for arsenite tolerance acquisition [23]. Hog1 is the ultimate MAPK of High Osmolarity 
Glycerol (HOG) pathway in yeast with both cytoplasmic (e.g. Fps1) and nuclear (e.g. Sko1, Hot1, Msn2/4) tar-
gets controlling set of different gens in response to hyper-osmotic stress [24]-[26]. However, the most important 
role of Hog1 in response to hyperosmotic stress concerns the control of glycerol accumulation [24] [27]. Hog1 
displays quantitative and qualitative differences in response to hyperosmotic and arsenite stress [23], neverthe-
less its kinase activity is required in response to both stress conditions [23] [28]. 
Hitherto, successful genetic modification attempts e.g. deleting the gene encoding for the MAPK of interest 
[23], constructing kinase dead allele of the MAPK [23] or deleting the terminal domain of aquaglyceroporins 
[23] have been executed, which result in higher arsenite uptake. However, such modifications may introduce ir-
reversible, compensatory and sometimes detrimental changes to the cells. 
The objective of this study was to develop a method to alter the cellular arsenite uptake (probably via Fps1) 
by employing Hog1 kinase inhibitor in yeast S cerevisiae. The employed Hog1 kinase inhibitor has previously 
been shown to selectively inhibit Hog1 kinase activity without targeting other MAPKs in S. cerevisiae [29]. The 
kinase activity of Hog1 is required for the feedback control and down regulation of HOG signaling [30]. Simi-
larly, a kinase dead version of Hog1 shows sustained phosphorylation in response to osmotic stress [30]. The in 
vivo activity of Hog1 inhibitor has therefore been shown by demonstrating a sustained Hog1 phosphorylation in 
response to osmotic stress in the presence of Hog1 inhibitor [29]. The effect has also been shown on single cell 
level through inhibiting the nuclear accumulation of Hog1 upon hyperosmotic stress, which requires its kinase 
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activity [29] [31]. In the current study, we have used Hsp104 heat shock protein as readout. Hsp104 is involved 
in refolding and reactivating denatured, aggregated proteins and is induced in response to different stresses e.g. 
heat, ethanol, arsenite and long-term storage in the cold [32]. Hsp104 has been shown to be evenly distributed 
throughout cytosol in unexposed cells. Arsenite exposure leads to protein misfolding, thereby triggering 
Hsp104-GFP redistribution to distinct foci (aggregates) [33], shown to be sites of protein aggregation [34] [35]. 
The aggregate formation occurs in an arsenite concentration dependent manner and is supposedly triggered by 
intracellular As(III) since the arsenite induced Hsp104-GFP foci are absent in the cells over expressing the plasma 
membrane-localized As(III) efflux pump Acr3 [33]. Although information obtained by traditional methods of 
molecular biology is absolutely valuable for understanding the ongoing intracellular processes, it is often insuf-
ficient and even misleading as the existing cell-to-cell variation is neglected. These variations may rise from in-
trinsic (e.g. variations in gene expression level) or extrinsic (e.g. difference in cell cycle stage) origins. There-
fore, we addressed the objective of this study at single cell level to count for such existing cell-to-cell variations. 
Here, using an interdisciplinary approach, which merges biology and physics we have used a fluorescence mi-
croscope platform combining microfluidics and optical tweezers. This experimental setup allows switching the 
cellular environment within seconds, which is otherwise a poor temporal resolution procedure at population lev-
el. It allows monitoring the response of individual cells over time using real-time microscopy imaging and high 
content cell screening in a microfluidic device in an automated manner. Moreover, it allows screening for vari-
ous inhibitors at diminutive quantity. This platform has previously been used to provide detailed information 
regarding vital aspects of cellular behavior, such as cell signaling and stress response [36]-[42]. 
2. Materials and Methods 
2.1. Yeast Strain and Cell Preparation Procedures 
Sacharomyces cerevisiae strain HSP104-GFP (BY4741HSP104-GFP-HIS3-MX6) (Invitrogen) cells were grown 
in Yeast Nitrogen Base (YNB, 6.7 g/l) with Complete Supplement Mixture (CSM, 1.54 g/l) and 2% glucose (pH 
= 6), at 30˚C on a shaker (220 rpm). The cells were collected at OD600 = 0.6 - 1.0. 
2.2. Inhibitor and Sodium Arsenite 
The selective Hog1 inhibitor 4-(1-benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)-N-isopropylpyridin-2-amine (M = 
478.67 g/mol) [29] [31] was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 1.9 mM stock 
solution. The final inhibitor concentration in YNB was 10 µm and incubation time was set to 5 minutes. 
Sodium arsenite (NaAsO2) (Sigma-Aldrich) was dissolved in water prior to use and applied to a final concen-
tration of 0.1 mM in YNB. 
2.3. Microfluidics and Microscopy 
The microfluidic device was fabricated using soft lithography as previously described [31] [43]. Just prior the 
experiment, glass syringes (Hamilton Company) containing the cells and different media respectively were at-
tached to the four-inlet microfluidic flow chamber via polytetrafluoro ethylene tubings (Cole-Parmer, Vernon 
Hills, IL, USA). Using a fiber-coupled ytterbium laser (YLD-5-LP, IPG Photonics) with a wavelength of 1070 
nm and estimated power of 240 mW in the laser focus [39], single cells were trapped and moved from the flow 
of the cell inlet channel. One by one, cells were then gently pressed against the bottom of the system to adhere 
and form a 5 × 5 cell array. The trapping procedure limited the cells exposure to the infrared light only for a few 
seconds (<10 s) to ensure minimized photo damage [44] [45]. The location of the cell array (120 µm, −10 µm) and 
the flow rates were determined by simulations of the velocity profiles and the concentration gradients in the 
system based on the diffusion coefficients of the fluids (Figures 1(a) and (b)) to ensure that cells are not sub-
jected to any substrate gradients but are fully covered by the specific treatment. Microenvironmental changes 
necessary for monitoring the Hsp104-GFP redistribution (aggregate formation), were created by changing the flow 
rates in the inlet channels (5, 5, 500 and 1000 nL/min for channels “1”, “2”, “3” and “4”, respectively) set by the 
syringe pumps (CMA 400, CMA Microanalysis). In this way, the environment could rapidly be changed from 
neutral media to a media containing Hog1 inhibitor, and thereafter to a media containing arsenite. The custom- 
written automation software in Open Lab (PerkinElmer, Waltham, MA, USA) used for trapping and positioning the  
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Figure 1. Simulation results for Hog1 inhibitor and arsenite in four-inlet microfluidic flow chamber. (a) Simulation results 
for the Hog1 inhibitor (10 µm) incubation in the microfluidic chamber. The flows in inlet channels 1 - 4 are set to 5, 5, 500 
and 5 nl/min respectively. Diffusion coefficient of the inhibitor is 2.4 × 10−10 m2/s. The color legend illustrates the concen-
tration of the substance and arrows show the velocity field inside the microfluidic channels. (b) Simulation results for the ar-
senite (0.1 mM) treatment in the microfluidic chamber. The flows in inlet channels 1 - 4 are set to 5, 5, 5 and 1000 nl/min 
respectively. Diffusion coefficient of sodium arsenite is 1.21 × 10−9 m2/s. The color legend illustrates the concentration of the 
substance and arrows show the velocity field inside the microfluidic channels.                                       
 
cells as well as controlling the syringe pumps, the microscope and the EM-CCD camera (C9100-12, Hamamatsu 
Photonics) used for the image acquisition, enabled an automated setup and maximized the control of the expe-
rimental process. For determining the number of aggregates, cells were imaged as z-stacks with nine focal layers 
spaced 0.8 µm apart. These images were acquired before and every 60 seconds for 5 minutes during inhibitor 
treatment or before and every 5 minutes for 60 minutes during arsenite treatment. The images were analyzed 
using CellStress software [46] and statistics were done using non-parametric Kruskal-Wallis tests. 
3. Results and Discussion 
3.1. Hog1 Kinase Inhibitor Treatment Leads to Elevated Arsenite Induced  
Hsp104-GFP Redistribution  
To examine whether treating cells with Hog1 kinase inhibitor results in increased arsenite influx into the cells, 
we compared the arsenite induced aggregate formation as a readout for increase in arsenite influx into the cells 
[33] in control and inhibitor treated cells. To address this issue, we first established that the condition in micro-
fluidic device in the presence of only growth media does not cause any aggregate formation (Figure 2). We next 
asked whether the Hog1 kinase inhibitor per se triggers Hsp104-GFP redistribution (aggregate formation). Based 
on previous study inhibiting Hog1 kinase activity with the applied inhibitor [31], (Hamngren, C. et al., submit-
ted), a range of concentrations between 5 μM to 25 μM of Hog1 kinase inhibitor and different incubation times 
were examined, of which the final concentration of 10 μM for a period of 5 minutes incubation was chosen as 
increasing concentration/incubation time could result in false aggregate formation. We monitored Hsp104-GFP 
relocalization in the cells positioned in the array upon exposure to growth media for 45 minutes after 5 minutes 
pretreatment with 10 μM inhibitor. Our data clearly showed that the applied inhibitor concentration and period 
of incubation does not promote aggregate formation within the investigated condition and time span (Figure 
3(a)). Although the total period of the experiments were initially set to 60 minutes, as some cells showed slight 
increase in aggregate formation around 50 minutes, the time lapse studies were instead performed to terminate at 
45 minutes to avoid any false aggregate formation. The late aggregate formation following incubation with 
Hog1 inhibitor might be explained by different scenarios. There is a possibility that incubation with the inhibitor  
D. Ahmadpour et al. 
 
 63 
   
(a)                                          (b) 
 
(c) 
Figure 2. Arsenite induces aggregate formation in a concentration dependent manner (as shown 
previously). Number of aggregates per cell upon different treatments; growth media (YNB) (65 
cells), 0.1 mM sodium arsenite (As) (46 cells) and 0.5 mM sodium arsenite (59 cells) at three time 
points ((a) 20, (b) 30 and (c) 40 minutes) in a four-inlet microfluidic flow chamber is presented. The 
aggregates are induced in the presence of arsenite in a concentration dependent manner and dis-
played in box plots as indicated. Statistics are calculated using non-parametric Kruskal-Wallis tests. 
(* = p < 0.05).                                                                       
 
either directly target the components involved in protein folding or result in stress conditions [32] e.g. oxidative 
stress [47] that triggers Hsp104 relocalization. The Hog1 inhibitor may also be partly non-specific and hence 
target other kinases in the cell resulting in eventual protein misfolding and Hsp104 redistribution. However, ad-
dressing the specificity of kinase inhibitors in yeast is rather difficult as panels of purified kinases are not com-
mercially available for such screens, whereas available for human kinases [48]. Another likely explanation 
would be that inhibition of the kinase activity of the Hog1 for a longer time leads to protein misfolding and the-
reby induction of heat shock protein responses. Hog1 kinase activity has been shown required to provide a ne-
cessary function to cope with unfolded protein accumulation due to ER stress [49]. Considering the fact that 
Hog1 becomes activated upon a wide variety of environmental cues and is involved in transcription, translation, 
transport, as well as cell cycle adaptations in response to different conditions [23] [24] [29], these are all plausi-
ble scenarios. These mechanisms are remained to be explored further in the future studies. However, in order to 
avoid conceivable synergetic aggregate formation, we have excluded the later time points when the few inhibitor 
induced aggregates occur. 
We next asked if arsenite is efficiently taken up by the cells when introduced in the flow and if it induces 
quantifiable Hsp104-GFP redistribution (aggregates) as reported before [33] in our setup. To this end, the cell 
arrays were subjected to the final concentration of 0.1 mM sodium arsenite and the aggregate formation was 
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followed by time lapse imaging every 5 minutes for 45 minutes. The results (Figure 3(b)) showed that arsenite 
is effectively taken up by cells (46 cells), induces Hsp104-GFP relocalization and arsenite induced aggregates 
were precisely quantifiable with the CellStress software [46]. The arsenite induced aggregate formation initiated 
roughly at 30 minutes after stress exposure. The maximum number of aggregates per cell found was six, the 
fraction of the cells showing aggregates after 45 minutes was slightly below 50% ranging from 1 to 4 aggregates 
per cell (Figure 3(b)) and the mean value of aggregates per cell was 0.85 (data not shown). As it was described 
earlier [33] we correlated the number of induced aggregates to the uptake/intracellular level of arsenite. This as-
sumption is bolstered by the fact that the induced aggregates indeed increase by arsenite concentration (Figure 2, 
[33]) whereas disappear upon over expression of arsenite export pump [33]. Our data also demonstrating that 
aggregate formation is not induced in normal condition in the presence of growth media (Figure 2) supports that 
the aggregate formation seen in arsenite-rich condition is likely not due to other stresses such as heat or cold 
stress but to the fact that the cells reside in arsenite supplemented growth media. However, this assertion could 
be supplemented and strengthened by traditional arsenite uptake assays. Nonetheless, the arsenite interference 
with protein folding and consequent aggregate formation does not contradict previously identified arsenite in-
duction of oxidative stress [50] and could also be the case in our experiments. 
To address whether the Hog1 kinase inhibitor is able to improve the arsenite uptake, we compared the arsenite 
induced aggregate formation in terms of increase in the number of cells having aggregates, increase in the num-
ber of aggregates per cell and time of initiation of aggregate formation in inhibitor treated and untreated condi-
tions. Cell arrays were exposed to 10 µm Hog1 inhibitor for 5 minutes and subsequently to 0.1 mM sodium ar-
senite for 45 minutes. Images were acquired prior and then every minute during the 5 minutes inhibitor treat-
ment. Subsequently, images were attained every 5 minutes during the arsenite exposure through the end of the 
time lapse experiment. Interestingly, the arsenite induced aggregate formation following pretreatment with the 
Hog1 kinase inhibitor initiated earlier (20 minutes compared to 30 minutes). The maximum number of aggregate 
per cell in this condition reached up to nine (compared to six), the fraction of the cells displaying aggregate for-
mation was about 80% after 45 minutes (compared to 50%) (Figure 3(c)) and the mean value of aggregates per 
cell (of in total 86 cells) was 2.35 times higher (2 vs. 0.85) (data not shown).  
Hence, we concluded that 1) the Hog1 inhibitor does not induce aggregate formation per se in the investigated 
time span and condition. However, as discussed earlier, the few aggregates formed at later time points might be 
due to inhibitor interference with protein folding, inhibitor induced stress conditions, the possibility of the inhi-
bitor being non-specific that in the long run could affect protein folding components or a consequence of long- 
term Hog1 inhibition; 2) the arsenite induced Hsp104-GFP redistribution [33] is reproducible when arsenite is 
introduced in the flow and is quantifiable in our setup. As previous and current data confirm, the aggregate for-
mation is indeed induced by arsenite, however, the mechanisms of Hsp104-GFP induction upon arsenite expo-
sure has been described elsewhere [33], and most importantly; 3) the short-term Hog1 kinase inhibitor treatment 
of the cells prior to arsenite treatment results in faster and increased aggregate formation both in terms of num-
ber of cells showing aggregate as well as number of aggregates per cell, probably due to the augmented arsenite 
uptake. 
We are the first to provide an approach in which small molecule, cell-permeable, fast acting and highly effi-
cient kinase inhibitor can act as powerful means to significantly (Figure 3(d)) elevate the arsenite induced ag-
gregates supposedly through elevated arsenite influx into the cells without any requirement for introducing ge-
netic modifications. Although, mechanisms behind this effect is not exclusively elucidated and requires further 
investigations, the current results together with our previous study [23] favors a possible mechanism (Figure 4) 
in which Fps1is negatively regulated by a kinase activate Hog1 [23]. However, in the presence of the inhibitor 
the kinase activity of Hog1 is partially impaired, which in turn leads to higher arsenite uptake via Fps1 indicated 
by higher number of arsenite induced aggregates. This hypothesis could be further evidenced e.g. by applying a 
truncated version of Fps1 that lacks the N-terminal regulatory domain rendering Fps1 constitutively open [51]. 
However, other players i.e. the possibility of inhibitor induced aggregate formation or other stress conditions such as 
oxidative stress induction of Hsp104-GFP relocalization are not ruled out (Figure 4). The fact that increase in 
arsenite uptake and thereby increase in the number of aggregates is partial is perhaps partly due to the incom-
plete inhibition of Hog1 [31] and partly due to the other existing arsenite detoxification mechanisms e.g. arsenite 
export pump Acr3 [52] and/or arsenite-glutathione conjugation and sequestration to the vacuole through the 
ABC transporter Ycf1 [53] (Figure 4) in the cell. Regardless of the cause, the partial nature of this MAPK inhi-
bition might have advantages as it prevents massive arsenite influx and severe, irreversible damage to the cells. 
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Figure 3. Hog1 kinase inhibitor increases the arsenite induced aggregate. Percentage of cells displaying the 
distribution of aggregates upon different treatments in a four-inlet microfluidic flow chamber over time. (a) 
Arrays of cells were treated with 10 μM Hog1 kinase inhibitor for 5 minutes. Thereafter, cells were incubated 
in growth media (Inhibitor-YNB) for 45 minutes. Aggregate formation was not induced under this condition 
(only 3 aggregates among 82 analyzed cells were induced after 45 minutes). (b) Arrays of cells (46 cells) were 
treated with 0.1 mM sodium arsenite (As) for 45 minutes. The aggregate formation initiated at 30 minutes and 
the maximum number of aggregates per cell reached up to 6. Also, the proportion of cells displaying aggre-
gates is increased over time (reaching approximately 50%). (c) Arrays of cells (86 cells) were treated with 10 
μM Hog1 kinase inhibitor for 5 minutes prior exposure to 0.1 mM sodium arsenite (Inhibitor-As) for 45 mi-
nutes. The aggregate formation initiated already at 20 minutes and the maximum number of aggregates per cell 
reached up to 9. The proportion of cells displaying aggregates reaches almost 80% at the final time point. (d) A 
box plot displaying the number of aggregates per cell formed at 45 minutes in the indicated cell treatments (as 
explained above). At 45 minutes, comparison using Kruskal-Wallis non-parametric test between the cell res-
ponses at all conditions show statistical significance. Already after 25 minutes, there was significant difference 
between cells treated with inhibitor-As and cells treated with only As (data not shown). (* = p < 0.05)          
3.2. Arsenite Accumulates to a Higher Degree in Mother Cells Compared to Their  
Daughters Following Inhibitor Treatment 
The cell-to-cell variation even exists in genetically homogenous populations. These variations may arise from 
intrinsic (differences in the expression levels of genes in the same cell) or extrinsic (cell-to-cell variation in a 
population) sources [54] [55]. The latter can partly be explained by fluctuations that occur through different cell 
cycle stages [56]. Therefore, we asked if the variation in response between mother cells and buds can to some 
extent explain the cell-to-cell variation in our results. To this end, we discriminated between mother and daugh-
ter cells (only attached buds) and examined whether the As(III) induced Hsp104-GFP relocalization (aggregate) 
shows a bimodal distribution between mother cells and their buds. The results showed no induced aggregate 
formation in mother cells (54 cells) or buds (28 cells) following inhibitor treatment (Figure 5(a)). Upon arsenite 
treatment, the number of aggregates was not substantially (Figure 5(d)) different in the mother cells (33 cells) 
compared to the buds (13 cells) (40% compared to the 60% respectively, Figure 5(b)), (mean value of 0.72 
compared to 1.1 per cell respectively, data not shown). Whereas, this difference was slightly more pronounced 
(Figure 5(d)) following kinase inhibitor treatment (mean value of 2.5 vs. 1.2 respectively, data not shown). The 
fraction of the mother cells (55 cells) showing aggregates compared to the buds (31 cells) was 90% to 60% re-
spectively and the maximum number of aggregates per cell was also higher in mother cells compared to the buds 
(9 compared to 5) (Figure 5(c)). More interestingly, the effect of kinase inhibitor treatment in increasing arse-
nite uptake was much more significant (Figure 5(d)) when it was studied only on discriminated mothers com-
pared to indiscriminated cells (mothers and buds together). While the mean number of aggregates in each moth-
er cell upon exposure to only arsenite was 0.7 the mean number of aggregates per each mother cell upon arsenite  
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Figure 4. Mechanisms involved in arsenite uptake and tolerance in S. cerevisiae. The uptake of trivalent form of 
arsenic (arsenite) is mediated by the glycerol channel Fps1 (1). The arsenite is then either extruded from the cell 
by arsenite export pump Acr3 (2) or conjugates to glutathione and sequesters to the vacuole through the ABC 
transporter Ycf1 (3). Hog1 is phosphorylated in response to arsenite and negatively modulates Fps1 transport ac-
tivity perhaps by phosphorylating Fps1 (4). Our results together with previous studies favor a model in which the 
Hog1 kinase inhibitor impairs the negative regulation of Hog1 on Fps1 (5) thereby increasing the arsenite uptake 
(6), which leads to increase in Hsp104-GFP redistribution (7). However, the other possible mechanisms involved 
in redistribution of Hsp104-GFP such as inhibition of proper protein folding, unspecific targeting other kinases 
leading to Hsp104 redistribution or effects related to long-term inhibition of Hog1 (8) are not ruled out.         
 
treatment post inhibitor exposure was 2.5 (data not shown) proving 3.6 times increase. This significant differ-
ence (Figure 5(d)) is very well reflected in the fraction of the mother cells showing aggregates upon arsenite 
treatment (40% Figure 5(b)) compared to the mother cells exposed to arsenite following inhibitor treatment (90% 
Figure 5(c)). In addition, the maximum number of aggregates following arsenite treatment after 45 minutes 
reaches up to 4 (Figure 5(b)) whereas upon inhibitor-arsenite exposure the maximum number of aggregates 
reaches up to 9 aggregates (Figure 5(c)). Collectively, our data indicates that the arsenite induced aggregates 
post kinase inhibitor treatment are more accumulated in mother cells compared to the buds. This bimodal beha-
vior may simply be a result of lower abundance of Fps1 in the plasma membrane of buds, different Hog1 to 
Fps1 protein expression ratios in buds compared to mother cells or higher uptake efficiency of inhibitors by 
mothers compared to buds. It can also be in line with the earlier observation where asymmetric inheritance of 
oxidatively damaged proteins and their accumulation in mother cells was reported to guarantee the fitness of 
newly born cells [57]. Previously, it has been shown that the otherwise cytosolic evenly distributed Hsp104-GFP 
redistributes to distinct foci, proved to be sites of protein aggregates [33]-[35]. Arsenite interferes with protein 
folding, induces protein aggregates and Hsp104 co-sediments with arsenite induced protein aggregates [33]. 
This complex here called as Hsp104-GFP aggregates seems to be asymmetrically distributed between mother 
and daughter cells, which might also be a way to provide fitness to the buds. 
4. Conclusion 
Arsenic carcinogenicity’s accumulation in crops and entering the food chain as a global threaten for human  
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Figure 5. Arsenite accumulates to a higher degree in mother cells 
compared to their daughters. The percentage of mother cells (M) 
and buds (B) displaying the distribution of aggregates upon differ-
ent treatments in a four-inlet microfluidic flow chamber over time. 
(a) The inhibitor treatment per se (Inhibitor-YNB) does not induce 
any aggregation in neither buds (28 cells) nor mother cells (54 
cells). While the number of aggregates at 45 minutes does not show 
dramatic difference between mothers (33 cells) and buds (13 cells) 
upon treatment with 0.1 mM arsenite (As) (b), this difference is 
slightly more pronounced in the combined inhibitor, sodium arse-
nite (Inhibitor-As) treatment (55 mother cells vs. 31 daughter cells) 
(c). In (d), the distribution of aggregates at the final time point is 
shown in a box plot. The difference between mothers and daugh-
ters is only significant at the end of the experiment and only in the 
condition of sequential arsenite and Hog1 inhibitor treatment. The 
effect of Hog1 kinase inhibitor in increasing the intracellular levels 
of arsenite and thereby the number of aggregates is even more sig-
nificant if this effect is investigated in only mother cells ((b) 
(mother cells) and (c) (mother cells). The statistics were performed 
using non-parametric Kruskal-Wallis tests. (* = p < 0.05)           
D. Ahmadpour et al. 
 
 68 
health [58] on the one hand, and paradoxical application of arsenic-based drugs in modern medical therapy [11] 
[14] [15] and appearance of resistant cancer cells and parasites [13] [18] [59] on the other hand necessitate the 
development of approaches in order to tune the arsenite entry into the cells based on purpose. Here, we (to our 
knowledge) are the first to propose a new approach to increase the cellular arsenite uptake using MAPK inhibi-
tor. This study is first to elucidate that in S. cerevisiae the arsenite uptake (probably through aquaglyceroporin 
Fps1) can be increased using a selective Hog1 kinase inhibitor. However, this assumption requires further inves-
tigations to be proven. The increased arsenite uptake post Hog1 kinase inhibitor treatment compared to only ar-
senite treatment was reflected both in the number of aggregates per cell (9 compared to 6 respectively), the frac-
tion of the cells showing aggregate (80% compared to 50% respectively) as well as the initiation time of aggre-
gate formation (30 minutes compared to 20 minutes respectively). Homologs to both MAPK Hog1 and aqua-
glyceroporin Fps1 are presented in many different organisms e.g. humans and plants, therefore similar ap-
proaches may paw the way for environmental and phytoremediation applications as well as for a more effective 
use of arsenite in medical therapy. As an example, increasing the arsenite uptake through arsenite transporting 
aquaglyceroporin AtNIP7; 1 in Arabidopsis thaliana [60] by inhibiting the respective MAPK can be an applica-
ble approach to phytoremediate the arsenite contaminated soil and irrigation water around culturing fields. The 
same approach may hold for increasing the uptake of arsenite through human aquaglyceroporins such as AQP7 
and AQP9 to increase the treatment efficacy using arsenic-based chemotherapeutic drugs for acute promyelocy-
ticleukemia [21]. However, extensive, case dependent studies and optimizations are required to step into a larger, 
applicable level of this approach. 
Moreover, we demonstrate a bimodal distribution of arsenite induced aggregates post kinase inhibitor treat-
ment between mother cells and daughter cells as the mean number of aggregates per cell was more pronounced 
in discriminated mother cells compared to discriminated daughter cells (2.5 vs. 1.2 respectively). Among other 
possible assumptions, this may be a result of higher arsenite uptake in mother cells compared to buds or a result 
of asymmetric inheritance of damaged proteins between mother and daughter yeast cells [57]. Alternatively, the 
rate of protein synthesis in buds compared to mother cells might be another factor affecting the asymmetrical 
distribution as arsenite seems to primarily target the proteins in the process of synthesis or folding [33]. Howev-
er, understanding the underlying mechanisms behind this asymmetrical distribution requires further detailed stu-
dies. 
Collectively, we believe that the presented approach can have great implications in environmental as well as 
medical and pharmaceutical applications. Besides, detailed understanding the yeasts’ “maternal” behavior is per 
se fascinating. 
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